Insulet Corporation (PODD)
-NasdaqGS 29.74 0.00(0.00%) May 21, 4:00PM EDT
| Prev Close: | 29.74 |
|---|
| Open: | 29.73 |
|---|
| Bid: | 22.66 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 27.15 |
|---|
| Beta: | 0.85 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 29.65 - 30.07 |
|---|
| 52wk Range: | 17.34 - 30.07 |
|---|
| Volume: | 438,034 |
|---|
| Avg Vol (3m): | 447,821 |
|---|
| Market Cap: | 1.59B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.97 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- INSULET CORP Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online(Mon, May 20)
- Medical Products Companies, Particularly Those Aimed at Surgical Procedures, Generating Substantial Free Cash and Showing High Returns on CapitalWall Street Transcript(Fri, May 17)
- INSULET CORP Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, May 17)
- Insulet Corporation to Present at Upcoming Investor ConferencesMarketwired(Wed, May 15)
- INSULET CORP FinancialsEDGAR Online Financials(Wed, May 15)
- INSULET CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Insulet downgraded by Northland CapitalBriefing.com(Wed, May 8)
- Insulet Beats Up on Analysts Yet Againat Motley Fool(Tue, May 7)
- Why Insulet Shares Poppedat Motley Fool(Tue, May 7)
- Insulet's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Mon, May 6)
- Insulet Earnings: Here’s Why Investors are Buying Shares Nowat Wall St. Cheat Sheet(Mon, May 6)
- Insulet Reports First Quarter 2013 ResultsMarketwired(Mon, May 6)
- INSULET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Mon, May 6)
- Q1 2013 Insulet Corporation Earnings Release - After Market CloseCCBN(Mon, May 6)
- Insulet to Develop New Version of the OmniPod Insulin Pump for Use With Humulin R U-500 Concentrated Insulin for People With Type 2 DiabetesMarketwired(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | 594.80 |
|---|
| P/S (ttm): | 7.19 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.59 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.18 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | -1.90 |
|---|
Business Summary
Insulet Corporation, a medical device company, engages in the development, manufacture, and sale of insulin infusion systems for people with insulin-dependent diabetes in the United States.
View More